$46.84
3.16% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

PTC Therapeutics, Inc. Stock price

$48.37
-4.50 8.51% 1M
+11.94 32.78% 6M
+3.23 7.16% YTD
+19.97 70.32% 1Y
+5.06 11.68% 3Y
+3.41 7.58% 5Y
-16.49 25.42% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.77 3.80%
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

Key metrics

Market capitalization $3.81b
Enterprise Value $3.06b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.80
P/S ratio (TTM) P/S ratio 4.73
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -13.97%
Revenue (TTM) Revenue $806.78m
EBIT (operating result TTM) EBIT $-146.75m
Free Cash Flow (TTM) Free Cash Flow $-114.19m
Cash position $1.14b
EPS (TTM) EPS $-4.73
P/E forward negative
P/S forward 5.28
EV/Sales forward 4.24
Short interest 8.38%
Show more

Is PTC Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

PTC Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a PTC Therapeutics, Inc. forecast:

8x Buy
53%
5x Hold
33%
2x Sell
13%

Analyst Opinions

15 Analysts have issued a PTC Therapeutics, Inc. forecast:

Buy
53%
Hold
33%
Sell
13%

Financial data from PTC Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
807 807
14% 14%
100%
- Direct Costs 118 118
59% 59%
15%
689 689
6% 6%
85%
- Selling and Administrative Expenses 225 225
157% 157%
28%
- Research and Development Expense 534 534
20% 20%
66%
-71 -71
32% 32%
-9%
- Depreciation and Amortization 76 76
69% 69%
9%
EBIT (Operating Income) EBIT -147 -147
58% 58%
-18%
Net Profit -363 -363
42% 42%
-45%

In millions USD.

Don't miss a Thing! We will send you all news about PTC Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PTC Therapeutics, Inc. Stock News

Neutral
PRNewsWire
6 days ago
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 35 new employees.
Negative
Reuters
6 days ago
PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug in January.
Neutral
PRNewsWire
6 days ago
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy.
More PTC Therapeutics, Inc. News

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Head office United States
CEO Matthew Klein
Employees 939
Founded 1998
Website www.ptcbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today